Microbiota characterisation and probiotic development - Sidjabat Group

Dr Hanna Evelina Sidjabat is currently a Chief Investigator within the Infection and Immunity Theme at the UQ Centre for Clinical Research. Dr Sidjabat focuses on probiotic research for gastrointestinal tract and upper airway health. The development of probiotics capable of decolonising antibiotic-resistant bacteria from the gastrointestinal tract is the emphasis of Dr Sidjabat's current work.

Dr. Sidjabat was the lead microbiologist of Professor Anders Cervin in research into upper respiratory tract microbiome and Australian Indigenous children with otitis media (Jan 2015 - Jul 2017). Dr Sidjabat will continue the microbiota characterisation and probiotic development of these otorhinolaryngology projects of Prof. Anders Cervin, i.e. the role of bacterial, fungal and viral sinus microbiome in chronic rhinosinusitis patients and characterisation of bacterial pathogens and commensals of otitis prone and non-otitis prone Australian Indigenous children - A&TSI BIOME Study: Aboriginal and Torres Strait Islander Bacterial Interference in Otitis Media, Explorative study.

Dr Sidjabat is a recognised expert in Australia in the area of molecular microbiology with over 13 years of experience working with antibiotic resistant Gram-negative bacteria. She was in charge of Prof. David L. Paterson's laboratory for 6.5 years at the University of Queensland Centre for Clinical Research. Prior to that, she was working at the Division of Infectious Diseases, University of Pittsburgh, Pennsylvania, USA under the supervision of A/Prof. Yohei Doi for 1.5 years. She has worked collaboratively with many leading microbiology laboratories nationally and internationally. Dr. Sidjabat communicates her research activities through www.facebook.com/probioticDD and twitter: @DrHannaSidjabat

  1. Probiotic discovery and development for gastrointestinal tract (GIT) capable in decolonising antibiotic resistant bacteria from GIT.
  2. Characterisation of genome sequence and proteome of pathogens and probiotics.
  3. Genome and proteome of Pseudomonas aeruginosa with acquired antibiotic resistance in cystic fibrosis patients.
  4. Nose and oral microbiota characterization as part of General Practitioners Antimicrobial Stewardship Programme Study (GAPS).

With the unnecessary use of antibiotics, antibiotic resistance is continuing to increase. One way to prevent the usage of antibiotics for infections is by maintaining balanced microbiota through probiotics. With our strong expertise in antibiotic resistance, comprehensive understanding of antibiotic resistance mechanisms and worldwide epidemiology, we are confident that the probiotics we develop will provide health benefits.

We are testing the probiotic strains we have developed against pathogens prevalent in Australia and in other parts of the world, so that our probiotics have the capability to be used worldwide. Our aim is to develop probiotics for future clinical trials for oral and topical administrations. We hope that the probiotics we are currently developing will one day be available in chemists.

You can help to reduce antibiotic resistance by supporting our probiotic research. To donate to probiotic research, click on the button below. When choosing a giving destination, please select "Other", then specify: Probiotic Research.

Donate